Skip to main content
Premium Trial:

Request an Annual Quote

Incyte Collaborates on Database with CVT

Premium

PALO ALTO, Calif.--CV Therapeutics and Incyte Pharmaceuticals have entered into a collaboration to develop a prototype gene expression database in the area of cardiovascular biology. The companies said the research program will address some major cardiovascular disease states, such as atherosclerosis and restenosis. Incyte will contribute its genomics capabilities, while CV will provide its molecular cardiology expertise.

Incyte will own the resulting data, and CV will receive a perpetual, nonexclusive license to use the data in its drug development efforts.

"The era of developing drugs by following the biological response of a single gene is drawing to a close," stated Richard Lawn, CV's vice-president of discovery research.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.